This inventor holds 1 USPTO granted patent and 1 published patent application and 2 EPO patents. Top assignee: Xomics Biopharma, Inc.. Active years: 2021.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2021
Title: The Innovative Contributions of Xuexiang Zhang
Introduction
Xuexiang Zhang is a prominent inventor based in Fremont, CA. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of methods to reduce the toxicity of platinum-based cancer drugs. His innovative work has the potential to improve treatment outcomes for cancer patients.
Latest Patents
Xuexiang Zhang holds a patent for "Methods of preventing toxicity of platinum drugs." This patent describes various methods for reducing platinum drug-induced toxicity in cells expressing Organic Cation Transporter 2 (OCT2). The methods include strategies for treating cancer and increasing the efficacy of platinum drug treatment in subjects. Notably, the patent also details pharmaceutical compositions that incorporate an OCT2 inhibitor, such as buflomedil or its salts, dolutegravir or its salts, and miconazole or its salts.
Career Highlights
Xuexiang Zhang is currently associated with Xomics Biopharma, Inc., where he continues to advance his research in the biopharmaceutical sector. His work focuses on enhancing the safety and effectiveness of cancer treatments, which is crucial for improving patient care.
Collaborations
Xuexiang collaborates with notable colleagues, including Yong Huang and Dominique Bridon. Their combined expertise contributes to the innovative research environment at Xomics Biopharma, Inc.
Conclusion
Xuexiang Zhang's contributions to the field of biopharmaceuticals, particularly through his patent on reducing platinum drug toxicity, highlight his role as an influential inventor. His ongoing work promises to make a significant impact on cancer treatment methodologies.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile